{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:26:33Z","timestamp":1793183193589,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03357-7","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T04:42:45Z","timestamp":1757738565000},"page":"5639-5652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Temporal Profile of Treatment-Emergent Adverse Events in Adult Asian Patients with Focal-Onset Seizures During Adjunctive Brivaracetam Treatment: Post Hoc Analysis of a Phase 3, Randomized Trial"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9736-7460","authenticated-orcid":false,"given":"Naotaka","family":"Usui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somsak","family":"Tiamkao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Cabral-Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2787-2365","authenticated-orcid":false,"given":"Kheng Seang","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1420-0970","authenticated-orcid":false,"given":"Shih-Hui","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Jane","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4575-9358","authenticated-orcid":false,"given":"Jun","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-7340","authenticated-orcid":false,"given":"Brian","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Bourikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"3357_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107212","volume":"111","author":"KJ Meador","year":"2020","unstructured":"Meador KJ, Laloyaux C, Elmoufti S, et al. Time course of drug-related treatment-emergent adverse side effects of brivaracetam. Epilepsy Behav. 2020;111:107212.","journal-title":"Epilepsy Behav"},{"issue":"9","key":"3357_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","volume":"35","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35(9):935\u201363.","journal-title":"CNS Drugs"},{"issue":"1\u20133","key":"3357_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","volume":"664","author":"M Gillard","year":"2011","unstructured":"Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664(1\u20133):36\u201344.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"3357_CR4","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/bjp.2008.198","volume":"154","author":"A Matagne","year":"2008","unstructured":"Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008;154(8):1662\u201371.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"3357_CR5","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/bjp.2008.221","volume":"154","author":"MA Rogawski","year":"2008","unstructured":"Rogawski MA. Brivaracetam: a rational drug discovery success story. Br J Pharmacol. 2008;154(8):1555\u20137.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"3357_CR6","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1007\/s12325-024-02876-z","volume":"41","author":"P Klein","year":"2024","unstructured":"Klein P, Bourikas D. Narrative review of brivaracetam: preclinical profile and clinical benefits in the treatment of patients with epilepsy. Adv Ther. 2024;41(7):2682\u201399.","journal-title":"Adv Ther"},{"key":"3357_CR7","unstructured":"UCB, Inc. BRIVIACT\u00ae (brivaracetam) United States prescribing information. https:\/\/www.ucb-usa.com\/briviact-prescribing-information.pdf. Accessed 16 Jul 2025."},{"key":"3357_CR8","unstructured":"UCB Pharma. Briviact EU summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/briviact-epar-product-information_en.pdf. Accessed 16 Jul 2025."},{"issue":"3","key":"3357_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/epi4.12929","volume":"9","author":"Y Inoue","year":"2024","unstructured":"Inoue Y, Tiamkao S, Zhou D, et al. Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia Open. 2024;9(3):1007\u201320.","journal-title":"Epilepsia Open"},{"key":"3357_CR10","unstructured":"The Pharmaceuticals and Medical Devices Agency. BRIVIACT\u00ae for I.V. injection 25mg. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/820110_1139406A1023_1_02. Accessed 4 Sep 2025."},{"key":"3357_CR11","unstructured":"The Pharmaceuticals and Medical Devices Agency. BRIVIACT\u00ae Tablets 25mg BRIVIACT\u00ae Tablets 50mg. www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/820110_1139017F1026_1_02. Accessed 4 Sep 2025."},{"issue":"3","key":"3357_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1212\/WNL.0000000000002864","volume":"87","author":"E Ben-Menachem","year":"2016","unstructured":"Ben-Menachem E, Mameni\u0161kien\u0117 R, Quarato PP, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016;87(3):314\u201323.","journal-title":"Neurology"},{"issue":"5","key":"3357_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/cts.12771","volume":"13","author":"C Lo","year":"2020","unstructured":"Lo C, Nguyen S, Yang C, et al. Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications. Clin Transl Sci. 2020;13(5):861\u201370.","journal-title":"Clin Transl Sci"},{"key":"3357_CR14","doi-asserted-by":"crossref","unstructured":"Usui N, Zhou D, Qin B, et al. Time course of treatment-emergent adverse events in adult Asian patients with focal-onset seizures during adjunctive brivaracetam treatment: a post hoc analysis of a phase III, randomized trial. https:\/\/aesnet.org\/abstractslisting\/time-course-of-treatment-emergent-adverse-events-in-adult-asian-patients-with-focal-onset-seizures-during-adjunctive-brivaracetam-treatment-a-post-hoc-analysis-of-a-phase-iii-randomized-trial. Accessed 16 Jul 2025.","DOI":"10.1007\/s12325-025-03357-7"},{"issue":"1","key":"3357_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/epi.12432","volume":"55","author":"P Ryvlin","year":"2014","unstructured":"Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47\u201356.","journal-title":"Epilepsia"},{"issue":"12","key":"3357_CR16","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1111\/epi.13212","volume":"56","author":"P Klein","year":"2015","unstructured":"Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890\u20138.","journal-title":"Epilepsia"},{"issue":"1","key":"3357_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/epi.12433","volume":"55","author":"V Biton","year":"2014","unstructured":"Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57\u201366.","journal-title":"Epilepsia"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03357-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03357-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03357-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:05:25Z","timestamp":1762261525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03357-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3357"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03357-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}